Core Laboratories Inc. CLB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -51.57% | -17.81% | 3.60% | -5.51% | 22.63% |
| Total Depreciation and Amortization | 2.29% | 0.84% | -0.88% | -2.03% | -3.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 787.91% | 662.01% | 679.08% | 235.95% | -128.25% |
| Change in Net Operating Assets | -518.54% | -326.49% | -183.91% | -284.41% | -1.83% |
| Cash from Operations | -50.32% | -48.02% | -40.30% | -34.33% | -9.97% |
| Capital Expenditure | -17.66% | -15.48% | -17.31% | -11.98% | -34.57% |
| Sale of Property, Plant, and Equipment | 21.02% | 24.37% | 38.10% | 73.73% | 215.32% |
| Cash Acquisitions | -0.49% | -0.49% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -94.73% | -28.95% | 3.46% | 115.99% | 110.60% |
| Cash from Investing | -599.95% | -76.37% | -61.26% | 65.11% | 61.41% |
| Total Debt Issued | 154.76% | 121.28% | 134.88% | 9.09% | -16.00% |
| Total Debt Repaid | -63.06% | -60.04% | -37.50% | 23.17% | 24.72% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 29.15% | -45.55% | -97.71% | -134.19% | -571.27% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 1.44% | 1.33% | 0.91% | 0.37% | 0.11% |
| Other Financing Activities | 90.52% | -1,413.99% | -894.44% | -152.90% | 2.10% |
| Cash from Financing | 66.27% | 21.98% | 41.26% | 31.99% | 3.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.36% | -162.65% | -90.10% | -12.19% | -14.47% |